Propoxyphene Marketing Halted By FDAAA-Required QT Safety Study
This article was originally published in The Pink Sheet Daily
The opioid, marketed under the Darvon and Darvocet brands and in generic form, has the ignominious distinction of being the first drug pulled from the market based on results of a post-marketing safety study required under the 2007 law.
You may also be interested in...
US FDA’s new draft guidance on benefit-risk assessments for new drugs highlights cases where it can take into account broader public health implications than just the pros and cons calculus for the patients described in a drug's label. While not a new policy perse, it is one the agency seems to have only grudgingly employed in the past.
Supreme Court asks the Solicitor General to weigh in on whether a state tort claim that Teva did not immediately update its generic Fosamax labeling is preempted by federal law; thousands of such suits have arisen in wake of high court’s Mensing decision.
FDA is trying multiple channels in social media to communicate drug safety information, but its two-way communication capacity is lower than many would like.